Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: CrayUSA who wrote (96723)	10/24/2003 9:47:59 AM
From: Findit	Read Replies (3) \| Respond to of 208838

In BOCX at .22 on news - RANCHO SANTA MARGARITA, Calif., Oct 24, 2003 (BUSINESS WIRE) --BioCurex Inc. (OTCBB:BOCX) is pleased to announce that extensiveevaluations of the company's RECAF(TM) cancer detection technologieshave commenced at Hopital Europeen Georges Pompidou in Paris, France. In the first stage, BioCurex's FDA approved Histo-RECAF(TM) kitwill be evaluated utilizing tissue sections (biopsies). Dr. DianeDamotte, Department of Pathology, Pompidou Hospital will lead thestudy. Dr. Damotte has expressed a keen interest in this project. Shehas also expressed the hope that once the initial study is completeher Department will be able to undertake further analysis ofBioCurex's RECAF(TM) marker technology. In the second stage, the Cancer Department at Pompidou Hospitalwould examine other aspects of the RECAF(TM) technology -- such asblood tests and tumor imaging. BioCurex's President and CEO, Dr. Ricardo Moro stated: "The workin Paris has another important consequence: The connection with theDepartment of Pathology came through Prof. Jean-Marie Andrieu, Head ofthe Department of Oncology at Pompidou. This association allowsBioCurex a unique opportunity to work with a whole team ofoncologists. We expect that this collaboration will result in acomprehensive evaluation of RECAF(TM)'s efficacy, including pathology,blood tests and tumor imaging. "Our initial studies indicate that the RECAF(TM) technology workson practically all types of cancer. However, we need to obtainindependent validation for each cancer type. This process is timeconsuming; there are many different kinds of cancer. Therefore, aspart of our overall strategy, we are engaging scientists in what canbe best defined as a multi-centric, international study. The work tobe done in France is necessary for the licensing of BioCurex'stechnology to European Biopharma companies." The aggregate market size for the two tests is estimated in over$2B per year. About BioCurex: BioCurex, Inc. is a biotechnology company that is developingproducts based on patented/proprietary technology in the areas ofcancer diagnosis, tumor imaging ad therapeutics. The technologyidentifies a cancer marker known as RECAF(TM), which is found onmalignant cells from a variety of cancer types but is absent in mostnormal or benign cells. The Histo-RECAF(TM) kits provide proof ofconcept for the RECAF technology. Detailed information about BioCurexmay be obtained from its Web site. Note: The Company has not authorized the release of this information inany form that contravenes the Communication Act and will not beresponsible for unsolicited massive distribution of this material bye-mail or facsimile by unauthorized parties. Statements in this pressrelease, which are not historical facts, are "forward-lookingstatements'' within the meaning given to that term in the PrivateSecurities Litigation Reform Act of 1995. The Company intends thatsuch forward-looking statements be subject to the safe harbors createdthereby. Since these statements involve risks and uncertainties andare subject to change at any time, the Company's actual results coulddiffer materially from expected results. NOTE TO EDITORS: In the hospital name, Hopital Europeen GeorgesPompidou, noted in this news release, there is a caret over the o inHopital and an accent-egu over the second e in Europeen. These symbolsmay not appear properly in some systems. SOURCE: BioCurex, Inc. BioCurex, Inc. Ricardo Moro, 866-884-8669 Fax: 866-437-2277 businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved.NewsProvided by COMTEX, comtex.com